Business
Nuvation Bio Announces Publication of Positive Phase 2 Study Results for Safusidenib for the Treatment of Grade 2 IDH1-Mutant Glioma in Neuro-Oncology
NEW YORK, December 03, 2025--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced the publication of positive results from a Phase 2 study of safusidenib, a novel, oral, potent, brain-penetrant targeted inhibitor of mutant IDH1, in patients with chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutant gliomas. The findings were first published online on November 8 in the journal of Neuro-Oncology.
About this update from Nuvation Bio Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":17689,"height":2887,"url":"https://media.zenfs.com/en/business-wire.com/26cffa9732afc39014605f1bd4d84838"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/OHT9KL0HftMo5FVQ6jPCKA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE1NztjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/26cffa9732afc39014605f1bd4d84838","width":960,"height":157},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/l5MyzmM1Y0tAUbZ45pXv.Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0zOTI7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/26cffa9732afc39014605f1bd4d84838","width":1200,"height":196}},"lazy":false},{"type":"text","content":"Safusidenib demonstrated durable responses, with an ORR of 44% and 88% of patients were progression-free at 24 months","length":117,"tagName":"p","attribs":{}},{"type":"text","content":"Findings supported recent favorable interactions with FDA where alignment was reached on modifying the ongoing G203 into a pivotal trial in high-grade gliomas","length":158,"tagName":"p","attribs":{}},{"type":"text","content":"NEW YORK, December 03, 2025--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced the publication of positive results from a Phase 2 study of safusidenib, a novel, oral, potent, brain-penetrant targeted inhibitor of mutant IDH1, in patients with chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutant gliomas. The findings were first published online on November 8 in the journal of Neuro-Oncology.","length":511,"tagName":"p"},{"type":"text","content":""Until recently, standard therapy for most IDH1-mutant gliomas was surgical resection followed by radiotherapy and chemotherapy, with only a subset of grade 2 patients undergoing active observation and delaying adjuvant chemoradiation and associated long-term toxicities," said David Reardon, M.D., Clinical Director of the Center for Neuro-Oncology at Dana-Farber Cancer Institute and a primary investigator for G203, the enrolling pivotal study of safusidenib in high-grade IDH1-mutant gliomas. "While approved IDH-inhibitors can now also be used to delay chemoradiation, the durability of benefit remains inadequate for many p...